

Press Release



ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Initiates Phase I/II Clinical Trial of Drospirenone Agent (LPRI-CF113) in Japan

TOKYO, March 10, 2025 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), announced that ASKA initiated a Phase I/II clinical trial in Japan for a novel drug (drospirenone agent, development code: LPRI-CF113, hereafter “the Drug”) in the field of obstetrics and gynecology in Japan, the product of which is owned by Insud Pharma (Head Office: Madrid, Spain) as announced on December 25, 2024.

The Drug is a continuously administered progestin agent based on a biphasic regimen of drospirenone. It is currently under development in Europe for the indication of “treatment of moderate to severe pelvic pain in women suffering from endometriosis seeking contraception” and in the United States for the indication of “the prevention of pregnancy in women of reproductive potential.” In Japan, ASKA will develop the Drug for the indication of “dysmenorrhea.”

ASKA announced a license agreement with Insud Pharma dated January 8, 2020, for a cyclical dosing agent (development code: LF111) consisting of 4 mg drospirenone for 24 days, followed by placebo tablets for 4 days. ASKA obtained its development and marketing rights in the Japanese and South Korean markets. On June 24, 2024, ASKA submitted an application for manufacturing and marketing approval as a contraceptive to regulatory authorities in Japan. On December 25, 2024, ASKA announced the expansion of its partnership with Insud Pharma and the conclusion of a license agreement for the Drug.

ASKA is strengthening its product lineup as a specialty pharma company specializing in the field of obstetrics and gynecology. Through the development of this Drug, ASKA will make further contributions to improving women's health and quality of life.

About Insud Pharma

Insud Pharma (<https://www.insudpharma.com/en/>) is a leading Spanish company with a track record in the pharmaceutical and healthcare industry spanning over 45 years. With 9,000 employees worldwide, Insud Pharma’s contribution to global public health is enormous, thanks to the medicines and APIs developed and manufactured at its three highly synergistic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience).

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp